Come up with a name for your new list and we'll add to it:
IgDraSol was acquired by
Sorrento Therapeutics on September 10, 2013.
IgDraSol is a private company focused on the development of oncologic agents for the treatment of metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC) and other cancers. IgDraSol's lead …